New therapy shows high remission rates for PTSD in trials
Wave Neuroscience developed a new brain therapy that achieved 68% remission for post-traumatic stress disorder during recent clinical trials.
This treatment combines brain activity mapping with personalized magnetic stimulation to target specific neural patterns unique to each patient. It represents a significant shift from standard protocols that apply generalized stimulation plans to everyone regardless of individual brain function.
Participants received five sessions weekly over five to six weeks while an AI algorithm built a custom plan based on recorded electrical activity data. Improvements in symptoms appeared to persist even after the scheduled treatment sessions officially ended for the group.
The new method adjusts stimulation based on real-time brain activity rather than covering issues with a generic approach used by standard devices. Researchers compared this targeted strategy to finding and replacing damaged shingles instead of simply placing a tarp over a leak.
This option stands as the first FDA-cleared non-drug treatment specifically designed for post-traumatic stress disorder alongside existing medication choices. Many patients previously struggled with anxiety-provoking psychotherapy requirements or dropped out due to difficult side effects from current drugs.
“This is the first time that in addition to the medication, we have a non-medication option.”